Navigation Links
Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
Date:6/8/2009

18 patients evaluable for efficacy achieved very good partial, partial or minor responses. Responses occurred in the first 28-day cycle of treatment at doses well below the maximum-tolerated dose for either lenalidomide or carfilzomib alone. Initial responses improved with continued therapy. Potent inhibition of the proteasome has been observed and the lenalidomide/dexamethasone combination does not appear to interfere with carfilzomib's activity.

"Results observed to date in our Phase 1b combination study of carfilzomib are very promising," said Michael Kauffman, M.D., Ph.D., Chief Medical Officer of Proteolix. "We believe that carfilzomib in combination with lenalidomide and dexamethasone should provide superior activity to lenalidomide and dexamethasone alone. In addition, the lack of overlapping toxicities and absence of peripheral neuropathy may allow for long-term dosing - and ultimately, sustained clinical benefit."

Dr. Wang presented interim data from the Phase 1b clinical trial during the Novel Therapeutics and Drug Resistance session in an oral talk, titled "#1070: PX-171-006: Phase IB Multicenter Dose Escalation Study of Carfilzomib (CFZ) plus Lenalidomide (LEN) and Low Dose Dexamethasone (LODEX) in Relapsed and Refractory Multiple Myeloma (MM) - Preliminary Results."

About Multiple Myeloma

According to the American Cancer Society, in 2009, approximately 20,500 new cases of multiple myeloma will be diagnosed in the United States. Newly diagnosed patients have treatment options that include combination chemotherapeutic agents and stem cell transplantation. While many patients respond to treatment, most eventually relapse and require subsequent treatment. Few patients are ultimately cured of their disease. In spite of advances in the treatment of multiple myeloma, this year alone, approximately 10,500 patients are expected to die of the disease.

About Carfilzomib<
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. Proteolix Raises $79 Million in Series C Financing
4. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
5. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
6. Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
7. Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting
8. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
9. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
10. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
11. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Unraveling life’s mysteries can intrigue, amaze, ... Family purchased a DNA test to unravel ... with a lifetime of memories, sharing, and closeness. In ... DNA genuinely brought the family closer together. , ... genetic history and prior to taking the genetic ...
(Date:7/10/2014)... Angeles, CA (PRWEB) July 10, 2014 ... and Bioanalytical techniques during 18-20 August, 2014 at Double ... critically review the recent developments in Analytical & Bioanalytical ... the globe. , Speaking on this occasion, Dr. Srinubabu ... Analytica Acta conference is a remarkable one in ...
(Date:7/10/2014)... Senior supply chain management executives from over ... challenges of “Reducing Cost, Lead Time, & Defects in ... Describing the partnership of the Bio Supply Management Alliance ... ( SCMI) of the University of San Diego ... Kroc Institute of Peace and Justice in San Diego, ...
(Date:7/10/2014)... On July 9 Prime Minister ... Russia,s first national "Industry" award ... is developing a unique project called MabNext . ... number of innovative drugs based on monoclonal antibodies for ... place at the International Exhibition "Innoprom 2014" in Ekaterinburg. ...
Breaking Biology Technology:Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... software developer Cedara Software and the ... to offer Cedara B-CAD to its customers as part ... Workstation. , ,Cedara B-CAD is a Computer Aided Detection ... lesions using ultrasound images, providing tools for automatic image ...
... individuals are invited to enter the 35th ... benefits coming from research and engineering of new ... Products Awards are given in four major categories: ... (500-999 employees); medium companies (50-499 employees); and small ...
... StrandVision , latest business venture of Mike Strand in ... last business-plan competition, has landed $250,000 from the ... Online Kiosks, has a plan to put video screens ... After reaching the statewide business-plan competition finals, it won ...
Cached Biology Technology:
(Date:7/14/2014)... inevitable consequence of aging? , Although it is widely ... the risk of developing several common cancers decreases with ... apparent decrease with age in the risk of developing ... this puzzle was presented in a recent paper published ... James P. Brody of the Department of Biomedical Engineering ...
(Date:7/14/2014)... developed a technology that could overcome a major ... a fuel that could replace expensive and environmentally ... a novel catalyst that performs almost as well ... use electric currents to split water molecules into ... far more efficient than less-expensive catalysts investigated to-date. ...
(Date:7/13/2014)... French . , ... led by the Research Institute of the McGill University ... oral medication is showing significant progress in restoring vision ... this inherited retinal disease that causes visual impairment ranging ... The study is published today in the scientific journal ...
Breaking Biology News(10 mins):Rutgers chemists develop technology to produce clean-burning hydrogen fuel 2MUHC researcher unveils novel treatment for a form of childhood blindness 2
... early stages, prostate cancer requires androgens (hormones that promote ... growth, and current first-line therapies target the receptor for ... However, advanced prostate cancers are often androgen-independent, ... sure how this shift occurs as prostate cancer advances. ...
... JERUSALEM , July 6, 2010 IDenta Corp.,(PINKSHEETS: IDTA) CEO Yaacov Shoham ... The IDenta,s BTK- Bullet Hole ... , , ... , http://www.lasvegassun.com/news/2008/jul/08/gee-whiz-packed-metro-csi-tru , ...
... just yet, but if you,re taking antioxidants because you hope ... the June 2010 issue of the journal GENETICS ... stress to our tissues shortens lifespan. That,s because researchers from ... genes of worms (genes believed to have counterparts in humans) ...
Cached Biology News:UNC team finds new target for treatment of advanced prostate cancer 2International Drug & Explosives Detection Company IDenta Corp Reports on BTK- Bullet Hole Testing Kit 2International Drug & Explosives Detection Company IDenta Corp Reports on BTK- Bullet Hole Testing Kit 3Want to slow aging? New research suggests it takes more than antioxidants 2
... Histone Deacetylase (HDAC) Antibody Sampler Kit ... (HDAC1) Antibody, Catalog #2062, 40 ul Histone ... ul Histone Deacetylase 4 (HDAC4) Antibody, Catalog ... Antibody, Catalog #2082, 40 ul Histone Deacetylase ...
An instrument that delivers an accurate and uniform amount of light energy to cells to photoactivate csiRNA products....
... Quickly, effectively seals labware. Waterproof, moisture-proof ... anhydrous materials. Can be folded repeatedly ... rupturing. Stretched lengthwise at 21C (70F), ... when tension is removed, film only ...
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Biology Products: